Nutra Pharma Overview
Valuation check: NPHC's ROE is 25.56%, above the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow25.56%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, NPHC shows a ROE of 25.56%. That is above the Healthcare sector average of 11.15%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 11.15%. Nutra Pharma is at 25.56%, which is higher that average. That is roughly 129.1% above the sector mean. Use the comparison chart on this page to see how NPHC stacks up against individual peers as well.
Check the historical chart to see whether NPHC's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Nutra Pharma with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Nutra Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 25.56%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 11.15%, while NPHC is at 25.56%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
